1. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity Featured Article: Ricardo V. Cohen, M.D., Jose C. Pinheiro, M.D., Carlos A. Schiavon, M.D., João E. Salles, M.D., Bernardo L. Wajchenberg, M.D., David E. Cummings, M.D. Diabetes Care Volume 35: 1420-1428 July, 2012

2. Study Objectives Cohen R et al. Diabetes Care 2012;35:1420-1428 Roux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients Study determined the long-term impact of RYGB on patients with diabetes and only class I obesity (BMI 30–35 kg/m 2 )

3. Study Design & Methods Sixty-six consecutively selected diabetic patients with BMI 30–35 kg/m 2 underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1–6]), with 100% follow-up Main outcome measures were safety and the percentage of patients experiencing diabetes remission (HbA1c < 6.5% without diabetes medication) Cohen R et al. Diabetes Care 2012;35:1420-1428

9. Conclusions Largest, longest-term study to date examining RYGB for diabetic patients without severe obesity RYGB safely and effectively ameliorated diabetes and associated comorbidities, reducing cardiovascular risk, in patients with a BMI of only 30–35 kg/m 2 Cohen R et al. Diabetes Care 2012;35:1420-1428